NTHI
NeOnc Technologies Holdings, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$131.61M
P/E Ratio
—
EPS
$-3.20
Beta
—
52W High
$12.99
52W Low
$3.20
50-Day MA
$8.90
200-Day MA
$8.17
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc. is a biotechnology company focused on the development and commercialization of cutting-edge cancer therapies, primarily through immunotherapy and molecular medicine. With a robust pipeline of innovative product candidates aimed at addressing significant unmet needs in oncology, NeOnc is well-positioned to transform treatment paradigms and improve patient outcomes. The company's strategic partnerships within the biopharmaceutical industry enhance its ability to advance its therapeutic innovations, making it a compelling investment opportunity in the fast-growing cancer therapeutics space.
Fundamentals
| Revenue (TTM) | 39,990 |
| Gross Profit (TTM) | 39,990 |
| EBITDA | — |
| Operating Margin | -145638.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1167.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.81 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 3290.98 |
| EV/Revenue | 3833.49 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $23.81M |
| Float | $8.15M |
| % Insiders | 61.05% |
| % Institutions | 8.95% |
Data last updated: 4/9/2026